Judge Karen Marston oversees consolidated GLP-1 stomach paralysis and vision loss lawsuits
Updated
Updated · AboutLawsuits.com · Apr 27
Judge Karen Marston oversees consolidated GLP-1 stomach paralysis and vision loss lawsuits
6 articles · Updated · AboutLawsuits.com · Apr 27
Over 3,300 stomach paralysis and more than 50 vision loss lawsuits against Novo Nordisk and Eli Lilly are consolidated in the Eastern District of Pennsylvania for bellwether trials.
These lawsuits allege severe injuries from GLP-1 medications like Ozempic, Wegovy, and Mounjaro, claiming manufacturers failed to warn about risks such as gastroparesis and NAION-related vision loss.
Recent research also raises concerns about potential links between long-term GLP-1 use and cognitive impairment, including dementia and Alzheimer’s, prompting calls for further study and ongoing litigation scrutiny.
Beyond weight loss, what are the hidden risks of stomach paralysis and vision loss from GLP-1 drugs?
Will thousands of lawsuits force Ozempic and Mounjaro makers to reveal undisclosed side effects?
As pharma giants battle, what does the future hold for safer weight-loss medications?
Are cheaper, compounded versions of Ozempic a safe alternative or a dangerous gamble?
Do weight-loss drugs cause dementia, or just help you live long enough to develop it?